These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3260620)

  • 1. Effects of interleukin-2 immunotherapy on renal function.
    Kozeny GA; Nicolas JD; Creekmore S; Sticklin L; Hano JE; Fisher RI
    J Clin Oncol; 1988 Jul; 6(7):1170-6. PubMed ID: 3260620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
    Margolin KA; Rayner AA; Hawkins MJ; Atkins MB; Dutcher JP; Fisher RI; Weiss GR; Doroshow JH; Jaffe HS; Roper M
    J Clin Oncol; 1989 Apr; 7(4):486-98. PubMed ID: 2647914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
    Webb DE; Austin HA; Belldegrun A; Vaughan E; Linehan WM; Rosenberg SA
    Clin Nephrol; 1988 Sep; 30(3):141-5. PubMed ID: 3263237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
    Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.
    Textor SC; Margolin K; Blayney D; Carlson J; Doroshow J
    Am J Med; 1987 Dec; 83(6):1055-61. PubMed ID: 3509745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
    Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
    J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
    Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
    J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
    Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
    N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
    J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.
    Belldegrun A; Webb DE; Austin HA; Steinberg SM; White DE; Linehan WM; Rosenberg SA
    Ann Intern Med; 1987 Jun; 106(6):817-22. PubMed ID: 3495213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion.
    Shalmi CL; Dutcher JP; Feinfeld DA; Chun KJ; Saleemi KR; Freeman LM; Lynn RI; Wiernik PH
    J Clin Oncol; 1990 Nov; 8(11):1839-46. PubMed ID: 2230870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.